| ［1］ |
Njoo MD, Das PK, Bos JD, et al. Association of the Köbner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris［J］. Arch Dermatol, 1999,135（4）:407⁃413.
|
| ［2］ |
Speeckaert R, Speeckaert M, De Schepper S, et al. Biomarkers of disease activity invitiligo: a systematic review［J］. Autoimmun Rev, 2017,16（9）:937⁃945. doi: 10.1016/j.autrev.2017.07.005.
|
| ［3］ |
Xiang W, Xu A, Xu J, et al. In vivo confocal laser scanning microscopy of hypopigmented macules: a preliminary comparison of confocal images in vitiligo, nevus depigmentosus and postin⁃flammatory hypopigmentation［J］. Lasers Med Sci, 2010,25（4）:551⁃558. doi: 10.1007/s10103⁃010⁃0764⁃2.
|
| ［4］ |
Bae JM, Lee SC, Katayama I, et al. Development and validation of the vitiligo extent score for target areas （VESTA）: an international collaborative study［J/OL］. Pigment Cell Melanoma Res, 2017,30:e58. doi: 10.1111/pcmr.12622.
|
| ［5］ |
Hamzavi I, Jain H, McLean D, et al. Parametric modeling of narrowband UV⁃B phototherapy for vitiligo using a novel quanti⁃tative tool: the Vitiligo Area Scoring Index［J］. Arch Dermatol, 2004,140（6）:677⁃683. doi: 10.1001/archderm.140. 6.677.
|
| ［6］ |
van Geel N, Lommerts J, Bekkenk M, et al. Development and validation of the Vitiligo Extent Score （VES）: an international collaborative initiative［J］. J Invest Dermatol, 2016,136（5）:978⁃984. doi: 10.1016/j.jid.2015.12.040.
|
| ［7］ |
Ezzedine K, Lim HW, Suzuki T, et al. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference［J］. Pigment Cell Melanoma Res, 2012,25（3）:E1⁃13. doi: 10.1111/j.1755⁃148X.2012.00997.x.
|
| ［8］ |
Rodrigues M, Ezzedine K, Hamzavi I, et al. Current and emerging treatments for vitiligo［J］. J Am Acad Dermatol, 2017,77（1）:17⁃29. doi: 10.1016/j.jaad.2016.11.010.
|
| ［9］ |
邱实, 樊奇敏, 胡慧丽, 等. 窄谱中波紫外线治疗白癜风疗效与相关因素的探讨［J］. 中华皮肤科杂志, 2014,47（4）:287⁃288.
|
| ［10］ |
林洁, 樊奇敏, 许爱娥. 窄谱中波紫外线治疗白癜风平台期相关研究［J］. 临床皮肤科杂志, 2016,45（6）:465⁃468.
|
| ［11］ |
Felsten LM, Alikhan A, Petronic⁃Rosic V. Vitiligo: a comprehensive overview Part II: treatment options and approach to treatment［J］. J Am Acad Dermatol, 2011,65（3）:493⁃514.
|
| ［12］ |
Siegfried EC, Jaworski JC, Hebert AA. Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice［J］. Am J Clin Dermatol, 2013,14（3）:163⁃178. doi: 10.1007/s40257⁃013⁃0020⁃1.
|
| ［13］ |
Cavalié M, Ezzedine K, Fontas E, et al. Maintenance therapy of adult vitiligo with 0.1 tacrolimus ointment: a randomized, double blind, placebo⁃controlled study［J］. J Invest Dermatol, 2015,135（4）:970⁃974. doi: 10.1038/jid.2014.527.
|
| ［14］ |
Ameen M, Exarchou V, Chu AC. Topical calcipotriol as mono⁃therapy and in combination with psoralen plus ultraviolet A in the treatment of vitiligo［J］. Br J Dermatol, 2001,145（3）:476⁃479.
|
| ［15］ |
Khullar G, Kanwar AJ, Singh S, et al.Comparison of efficacy and safety profile of topical calcipotriol ointment in combination with NB⁃UVB vs. NB⁃UVB alone in the treatment of vitiligo: a 24⁃week prospective right⁃left comparative clinical trial［J］. J Eur Acad Dermatol Venereol, 2015,29（5）:925⁃932. doi: 10.1111/jdv.12726.
|
| ［16］ |
de Menezes AF, Oliveira de Carvalho F, Barreto RS, et al. Pharmacologic treatment of vitiligo in children and adolescents: a systematic review［J］. Pediatr Dermatol, 2017,34（1）:13⁃24. doi: 10.1111/pde.13024.
|
| ［17］ |
Margolis DJ, Abuabara K, Hoffstad OJ, et al. Association between malignancy and topical use of pimecrolimus［J］. JAMA Dermatol, 2015,151（6）:594⁃599. doi: 10.1001/jamadermatol.2014.4305.
|
| ［18］ |
Oiso N, Kawada A. Freckling promoted by topical tacalcitol in a Japanese boy with left eyelid vitiligo. Pediatr Dermatol, 2012,29（5）:671⁃672. doi: 10.1111/j.1525⁃1470.2011.01559.x.
|
